Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

S32006

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
The antidepressive drug agomelatine combines the properties of an agonist of melatonergic receptors 1 and 2 with an antagonist of… Expand
2013
2013
Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in… Expand
  • table 1
2013
2013
This study examined in naive or hemiparkinsonian rats the effect of various serotonin 2C (5-HT(2C)) receptor ligands differing in… Expand
2012
2012
The novel melatonergic agonist/5-HT(2C) antagonist agomelatine displays robust antidepressant properties in humans and is active… Expand
2011
2011
The novel antidepressant, agomelatine, behaves as an agonist at melatonergic receptors, and as an antagonist at edited, human… Expand
Highly Cited
2010
Highly Cited
2010
Abstract Objectives. The aim of this study was to investigate the acute modulation of the neurotrophin Brain-derived neurotrophic… Expand
Highly Cited
2010
Highly Cited
2010
BackgroundAgomelatine is a melatonergic receptor agonist and a 5HT2C receptor antagonist that has shown antidepressant efficacy… Expand
  • figure 1
Highly Cited
2009
Highly Cited
2009
Agomelatine is a novel antidepressant acting as a melatonergic receptor agonist and serotonergic (5-HT2C) receptor antagonist. In… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2009
2009
RationaleThe novel antidepressant, agomelatine, behaves as an agonist at melatonin MT1 and MT2 receptors and as an antagonist at… Expand
  • figure 4
Highly Cited
2008
Highly Cited
2008
RationaleSerotonin (5-HT)2C receptors are implicated in the control of mood, and their blockade is of potential interest for the… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4